PMID- 26542862
OWN - NLM
STAT- MEDLINE
DCOM- 20160928
LR  - 20151106
IS  - 1879-0267 (Electronic)
IS  - 0020-1383 (Linking)
VI  - 46 Suppl 4
DP  - 2015 Oct
TI  - Defect type, localization and marker gene expression determines early adverse 
      events of matrix-associated autologous chondrocyte implantation.
PG  - S2-9
LID - S0020-1383(15)30012-7 [pii]
LID - 10.1016/S0020-1383(15)30012-7 [doi]
AB  - INTRODUCTION: Since the first description of autologous chondrocyte implantation 
      (ACI) in 1994 different methods and improvements were established for this 
      regenerative treatment option of large chondral defects. This study analyzes 
      safety and short-term clinical results from characterized ACI using a collagen 
      based biphasic scaffold and evaluates prognostic factors. METHODS: 433 patients 
      with a mean age of 33.4 years and localized grade III to IV cartilage defects 
      (ICRS classification) in the knee or ankle were included. Mean defect size was 
      5.9 cm(2). Prior seeding of the scaffold, expanded chondrocytes were 
      characterized by RT-PCR on 6 different marker genes (type I and II collagen, 
      aggrecan, interleukin-1 beta (IL-1beta), vascular endothelial growth factor receptor 1 
      (FLT-1) and bone sialoprotein-2 (BSP-2)). Clinical outcome was evaluated using a 
      questionnaire for defect history, basic demographics, time elapsed from surgery, 
      10-point outcome assessments of pain, function and swelling. Moreover, adverse 
      events (AEs) or subsequent treatments were recorded and analysed. RESULTS: 
      Patients improved significantly over baseline (p < 0.0001) in pain, function and 
      swelling. Subjects with later than 12 months follow-up reported nominally greater 
      mean changes. Graft failure incidence was 6% for patients with greater than one 
      year follow-up. Graft-related complications were significantly higher for 
      patellar (p < 0.0001) and degenerative defects (p = 0.005). Elevated expression 
      of FLT-1 (p = 0.02) or IL-1 beta mRNA (p = 0.03) was associated with graft-related 
      AEs. A borderline association was found for low collagen type II expression (p = 
      0.08). CONCLUSION: Early graft-related AEs after ACI with a biphasic collagen 
      scaffold are related to defect type, location and marker gene expression. The 
      levels of significance observed for gene expression with respect to graft-related 
      AEs were subordinate to those identified in the analysis of lesion history and 
      location.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Angele, Peter
AU  - Angele P
AD  - Department of Trauma Surgery, University Medical Centre Regensburg, Germany; 
      Sporthopaedicum Regensburg, Germany. Electronic address: peter.angele@ukr.de.
FAU - Fritz, Juergen
AU  - Fritz J
AD  - Orthopadisch Chirurgisches Zentrum Tubingen, Germany.
FAU - Albrecht, Dirk
AU  - Albrecht D
AD  - Klinik im Kronprinzenbau, Reutlingen, Germany.
FAU - Koh, Jason
AU  - Koh J
AD  - Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern 
      University, Chicago, Illinois, USA.
FAU - Zellner, Johannes
AU  - Zellner J
AD  - Department of Trauma Surgery, University Medical Centre Regensburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Netherlands
TA  - Injury
JT  - Injury
JID - 0226040
RN  - 0 (Collagen Type I)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adult
MH  - Ankle Injuries/metabolism/physiopathology/*therapy
MH  - Cartilage Diseases/physiopathology/*therapy
MH  - Cartilage, Articular
MH  - *Cell Transplantation
MH  - Chondrocytes/*transplantation
MH  - Collagen Type I/metabolism
MH  - Female
MH  - Graft Survival
MH  - Humans
MH  - Interleukin-1beta/metabolism
MH  - Knee Injuries/metabolism/physiopathology/*therapy
MH  - Male
MH  - Range of Motion, Articular
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Transplantation, Autologous
MH  - Vascular Endothelial Growth Factor A/metabolism
OTO - NOTNLM
OT  - MACT
OT  - adverse events
OT  - cartilage defect
OT  - cell characterization
OT  - short-term clinical outcome
EDAT- 2015/11/07 06:00
MHDA- 2016/09/30 06:00
CRDT- 2015/11/07 06:00
PHST- 2015/11/07 06:00 [entrez]
PHST- 2015/11/07 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - S0020-1383(15)30012-7 [pii]
AID - 10.1016/S0020-1383(15)30012-7 [doi]
PST - ppublish
SO  - Injury. 2015 Oct;46 Suppl 4:S2-9. doi: 10.1016/S0020-1383(15)30012-7.